MARGARET A. SHIPP, M.D.; DAVID P. HARRINGTON, Ph.D.; MARY M. KLATT, M.A.; MAXINE S. JOCHELSON, M.D.; GERALDINE S. PINKUS, M.D.; JESSICA L. MARSHALL, B.S.; DAVID S. ROSENTHAL, M.D.; ARTHUR T. SKARIN, M.D.; GEORGE P. CANELLOS, M.D.
SHIPP MA, HARRINGTON DP, KLATT MM, JOCHELSON MS, PINKUS GS, MARSHALL JL, et al. Identification of Major Prognostic Subgroups of Patients with Large-Cell Lymphoma Treated with m-BACOD or M-BACOD. Ann Intern Med. 1986;104:757-765. doi: 10.7326/0003-4819-104-6-757
Download citation file:
Published: Ann Intern Med. 1986;104(6):757-765.
One hundred twenty-one patients with diffuse large-cell lymphoma treated with m- or M-BACOD (methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone) were evaluated for pretreatment characteristics predictive for response and survival. Two characteristics, poor performance status and massive bulky disease, were negatively associated with response rate in a multivariate analysis. These two characteristics were also negatively associated with survival in multivariate analysis, as was another factor, an increased number of extranodal sites of disease. These three pretreatment characteristics were used to construct a model containing 12 categories of patients at increasing risk for relapse and shortened survival. These categories divided naturally into three broad groups of patients with respective 5-year survival rates of 68%, 55%, and 24%.
Learn more about subscription options.
Register Now for a free account.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only